Takeda Presents Phase 2 Data On Maintenance With Single-Agent Investigational Ixazomib In Patients With Newly Diagnosed Multiple Myeloma - Data Featured as Oral Presentation at ASH 2014 - SAN FRANCISCO-- --Takeda Pharmaceutical Company Limited today announced results from an open-label, Phase 2 study evaluating the safety and efficacy of oral, single-agent ixazomib as maintenance therapy in patients with multiple myeloma who had received ixazomib, lenalidomide and dexamethasone as induction therapy. The data from this trial demonstrate the potential feasibility of single-agent ixazomib maintenance therapy following 12 cycles of ixazomib-lenalidomide-dexamethasone, with deepening responses and an acceptable tolerability profile.
http://ift.tt/1zjbWif
http://ift.tt/1zjbWif
No comments:
Post a Comment